Advertisement

On the Normative Foundations of Pharmaceutical Regulation

  • David TeiraEmail author
Chapter
  • 18 Downloads
Part of the Boston Studies in the Philosophy and History of Science book series (BSPS, volume 338)

Abstract

I argue that behind the 1962 Food and Drug Administration Act we find a combination of two normative principles: a liberal argument for the protection of pharmaceutical markets (in terms of quality control) and a paternalist argument for the protection of pharmaceutical consumers (in terms of drug safety and efficacy). These normative intuitions go hand in hand with the choice of regulatory testing standards: depending on the values the regulator wants to protect, she will avail herself of different testing methods. I explore two potential justifications for regulatory paternalism, in terms of risk aversion and impartiality. I defend our current regulatory arrangement against socialist and libertarian critiques.

Notes

Acknowledgements

I am grateful to the editors, Bennett Holman and Julian Reiss for their detailed comments on a previous draft. My research was funded by the grant FFI2014-57258-P The paper was written during my stay at the Instituto de Investigaciones Filosóficas (UNAM, Mexico) with a PREI grant that I gratefully acknowledge. I thank Atocha Aliseda and various audiences at UNAM for their insightful discussion.

References

  1. Anderson, O. (1958). The health of a nation: Harvey W. Wiley and the fight for pure food. Chicago: University of Chicago Press.Google Scholar
  2. Boldrin, M., & Levine, D. K. (2008). Against intellectual monopoly. New York: Cambridge University Press.Google Scholar
  3. Borgerson, K. (2009). Valuing evidence Bias and the evidence hierarchy of evidence-based medicine. Perspectives in Biology and Medicine, 52(2), 218–233.CrossRefGoogle Scholar
  4. Carpenter, D. P. (2010). Reputation and power: Organizational image and pharmaceutical regulation at the FDA. Princeton: Princeton University Press.Google Scholar
  5. Carpenter, D. P. (2014). Corrosive capture? The dueling forces of autonomy and industry influence in FDA pharmaceutical regulation. In D. Carpenter & D. A. Moss (Eds.), Preventing regulatory capture: Special interest influence and how to limit it (pp. 152–171). New York: Cambridge University Press.Google Scholar
  6. Carpenter, D., & Moore, C. (2007). Robust action and the strategic use of ambiguity in a bureaucratic cohort: FDA scientists and the investigational new drug regulations of 1963. In S. Skowronek & M. Glassman (Eds.), Formative acts (pp. 340–362). Philadelphia: University of Pennsylvania press.Google Scholar
  7. Carpenter, D., & Sin, G. (2007). Policy tragedy and the emergence of economic regulation: The food, drug and cosmetic act of 1938. Studies in American Political Development, 21(2), 149–180.CrossRefGoogle Scholar
  8. Carpenter, D., Zucker, E. J., & Avorn, J. (2008). Drug-review deadlines and safety problems. New England Journal of Medicine, 358(13), 1354–1361.CrossRefGoogle Scholar
  9. Epstein, S. (1996). Impure science. Aids and the politics of knowledge. Berkeley/Los Angeles: University of California Press.Google Scholar
  10. Gabriel, J. M. (2014). Medical monopoly: Intellectual property rights and the origins of the modern pharmaceutical industry, synthesis. Chicago: The University of Chicago Press.CrossRefGoogle Scholar
  11. Goldacre, B. (2013). Bad pharma: How drug companies mislead doctors and harm patients. (First American ed.). New York: Faber and Faber, Inc., an affiliate of Farrar, Straus and Giroux.Google Scholar
  12. González De Prado Salas, J., & Teira, D. (2015). Choosing expert statistical advice: Practical costs and epistemic justification. Episteme, 12(1), 117–129.CrossRefGoogle Scholar
  13. Gøtzsche, P. C. (2013). Deadly medicines and organised crime: How big pharma has corrupted healthcare. London: Radcliffe Publishing.Google Scholar
  14. Greene, J. A. (2014). Generic: The unbranding of modern medicine. Baltimore: Johns Hopkins University Press.Google Scholar
  15. Holman, B. (2015). The fundamental antagonism: Science and commerce in medical epistemology. PhD, University California Irvine.Google Scholar
  16. Hróbjartsson, A., Thomsen, A. S. S., Emanuelsson, F., Tendal, B., Hilden, J., Boutron, I., Ravaud, P., & Brorson, S. (2012). Observer bias in randomised clinical trials with binary outcomes: Systematic review of trials with both blinded and non-blinded outcome assessors. BMJ, 344, e111.CrossRefGoogle Scholar
  17. Jack, D. B., & Mason, N. P. (1987). The pharmaceutical industry in the U.S.S.R. Journal of Clinical Pharmacy and Therapeutics, 12(6), 401–407.CrossRefGoogle Scholar
  18. Jackson, C. O. (1970). Food and drug legislation in the New Deal. Princeton: Princeton University Press.Google Scholar
  19. Jain, S. (2007). Understanding physician-pharmaceutical industry interactions. Cambridge/New York: Cambridge University Press.CrossRefGoogle Scholar
  20. Landes, J., Osimani, B., & Poellinger, R. (2017). Epistemology of causal inference in pharmacology. European Journal for Philosophy of Science, 8, 1–47.  https://doi.org/10.1007/s 13194-017-0169-1.CrossRefGoogle Scholar
  21. Lasagna, L. (1959). Gripesmanship: A positive approach. Journal of Chronic Diseases, 10, 459–468.CrossRefGoogle Scholar
  22. Levine, R. J. (1986). Ethics and regulation of clinical research (2nd ed.). Baltimore: Urban & Schwarzenberg.Google Scholar
  23. Marks, H. M. (1997). The progress of experiment. Science and therapeutic reform in the United States, 1900–1990. New York: Cambridge University Press.Google Scholar
  24. McCoy, G. W. (1920). Official methods of control of remedial agents for human use. Journal of the American Medical Association, 74(23), 1553–1555.CrossRefGoogle Scholar
  25. Okun, M. (1986). Fair play in the marketplace: The first battle for pure food and drugs. Dekalb: Northern Illinois University Press.Google Scholar
  26. Peterson, K. (2014). Speculative markets: Drug circuits and derivative life in Nigeria, experimental futures: Technological lives, scientific arts, anthropological voices. Durham/London: Duke University Press.CrossRefGoogle Scholar
  27. Podolsky, S. H. (2015). The antibiotic era: Reform, resistance, and the pursuit of a rational therapeutics. Baltimore: Johns Hopkins University Press.Google Scholar
  28. Reiss, J. (2017). Meanwhile, why not biomedical capitalism? In K. Elliott & D. Steel (Eds.), Current controversies in science and values (pp. 161–175). Routledge: New York.CrossRefGoogle Scholar
  29. Senn, S. (2008). Lessons from TGN1412 and TARGET: Implications for observational studies and meta-analysis. Pharmaceutical Statistics, 7(4), 294–301.CrossRefGoogle Scholar
  30. Sheps, M. C. (1961). The clinical value of drugs: Sources of evidence. American Journal of Public Health & the Nation’s Health, 51(5), 647–654.CrossRefGoogle Scholar
  31. Spellecy, R. (2003). Reviving Ulysses contracts. Kennedy Institute of Ethics Journal, 13(4), 373–392.CrossRefGoogle Scholar
  32. Teira, D. (2013a). On the impartiality of early British clinical trials. Studies in History and Philosophy of Biological and Biomedical Sciences, 44(3), 412–418.  https://doi.org/10.1016/ j.shpsc.2013.05.003. CrossRefGoogle Scholar
  33. Teira, D. (2013b). A contractarian solution to the experimenter’s regress. Philosophy of Science, 80(5), 709–720.CrossRefGoogle Scholar
  34. Teira, D. (2017). Testing oncological treatments in the era of personalized medicine. In G. Boniolo & M. Nathan (Eds.), Philosophy of molecular medicine (pp. 236–251). London: Routledge.Google Scholar
  35. Vardon, P. J. (2003). The constitutional political economy of the new drug approval process: Between reason and success. Economics, George Mason University.Google Scholar
  36. Wardell, W. M., & Lasagna, L. (1975). Regulation and drug development. Washington D. C.: American Enterprise Institute for Public Policy Research.Google Scholar
  37. Wilson, C. (2008). Adverse selection. In S. N. Durlauf & L. E. Blume (Eds.), The new Palgrave dictionary of economics. Basingstoke: Palgrave Macmillan.Google Scholar
  38. Worrall, J. (2002). What evidence in evidence-based medicine? Philosophy of Science, 69(3 Supplement), S316–S330.CrossRefGoogle Scholar
  39. Worrall, J. (2007). Why there’s no cause to randomize. British Journal for the Philosophy of Science, S 58(3), 451–488.CrossRefGoogle Scholar
  40. Young, J. H. (1989). Pure food: Securing the federal food and drugs act of 1906. Princeton: Princeton University Press.CrossRefGoogle Scholar
  41. Young, J. H. (1992). American health quackery: Collected essays. Princeton: Princeton University Press.CrossRefGoogle Scholar
  42. Zamora, J. (2002). Scientific inference and the pursuit of fame: A contractarian approach. Philosophy of Science, 69, 300–323.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Universidad Nacional de EducaciónMadridSpain

Personalised recommendations